Sat, Dec 27, 2014, 9:49 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Anika Therapeutics, Inc. (ANIK) Message Board

  • jesse.livermore jesse.livermore Feb 17, 2011 12:20 PM Flag


    Never have I seen a board with so many rabid pumpers half of them complaining about shorts...Shorts could not get a word in edgewise here. You think if you all get together and start repeating "ANIK is great", "ANIK is great" its going to turn this into a winner...Very few of you really understand what the situation is. You think for example because ANIK has four products FDA ready that this is all she wrote. IMHO ANIK will get all four products's that.

    The problem is the products are not getting FDA approval as drugs, but as devices and this makes the approval process easier and much faster. The "devices" are all Hyaluronic Acid (HA) based . The FDA pretty much "rubber stamps" these thru, because face it there is a lot of them. HA products are easy to copy, because HA is polymetric and all that is necessary is to change the chain length and Voila!! a new Monovisc..

    I am no stranger to Anika..Their old facility was in Woburn Mass, just down the road from my office. I have used their product Ellevess, now named Hydrelle, when it first came out. Hydrelle is HA facial "filler" used for wrinkle reduction and volume expansion. The product was good, in my hands it seemed to give a greater effect at comparible volumes then the other fillers at the time. It also was the first to include local anesthetic, a big deal. There are currently at least five other HA fillers competing for the Derm/PS market. Despite being a very good product, Hydrelle has not been sucessful..One reason, Anika's CEO apparently got into an argument with their marketing company and the marketers dropped Anika.

    If you "play" this stock it will most likely go up with the FDA approvals...posters and others do not understand that these are not that important..The problem is competition. Easy to copy and ease of approval, cuts into market share and margins..That's why the Italian company could not make a profit...

    Was talking with the J&J rep yesterday...They are coming with another "HA filler" He said J&J will cut the price way down, and does not expect to make a profit from the filler...They are merely doing it to increse their presence in the cosmetic surg market...


    SortNewest  |  Oldest  |  Most Replied Expand all replies
39.04+0.78(+2.04%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Prothena Corporation plc
NASDAQFri, Dec 26, 2014 4:00 PM EST
TherapeuticsMD, Inc.
AMEXFri, Dec 26, 2014 4:01 PM EST